Beyond "Psychotropic": Repurposing Psychiatric Drugs for COVID-19, Alzheimer's Disease, and Cancer.

Lenze, Eric J; Reiersen, Angela M; Zorumski, Charles F; Santosh, Paramala J

Lenze, Eric J; Reiersen, Angela M; Zorumski, Charles F; Santosh, Paramala J.

Affiliation

Lenze EJ; Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri.
Reiersen AM; Corresponding author: Eric Lenze, MD, 660 S Euclid Box 8134, St Louis, MO 63110 (lenzee@wustl.edu).
Zorumski CF; Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri.
Santosh PJ; Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri.

J Clin Psychiatry ; 84(3)2023 03 20.

Article in En | MEDLINE | ID: mdl-36946597

Subject(s)

Alzheimer Disease; COVID-19 Drug Treatment; COVID-19; Drug Repositioning; Mental Disorders; Neoplasms; Psychotropic Drugs; COVID-19/complications; Alzheimer Disease/drug therapy; Neoplasms/drug therapy; Mental Disorders/complications; Mental Disorders/drug therapy; Humans; Animals; Fluvoxamine/therapeutic use; Psychotropic Drugs/therapeutic use; Selective Serotonin Reuptake Inhibitors/therapeutic use; Post-Acute COVID-19 Syndrome/complications; Post-Acute COVID-19 Syndrome/drug therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psychotropic Drugs / Drug Repositioning / Alzheimer Disease / COVID-19 / COVID-19 Drug Treatment / Mental Disorders / Neoplasms Type of study: Clinical_trials / Diagnostic_studies / Guideline Limits: Animals / Humans Language: En Journal: J Clin Psychiatry Year: 2023 Type: Article

Fulltext

XML

PubMed Links

Search on Google